“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.
The UroActive System is currently under investigation in 2 first-in-human clinical trials in male and female patients with SUI.
“These NIAGARA data show for the first time that adding durvalumab to chemotherapy before surgery followed by durvalumab extends patients’ lives," says Thomas Powles, MD.
A phase 1 trial of ADI-270 in clear cell RCC is expected to launch in the second half of 2024.
The fast track designation for BNT324/DB-1311 is supported by safety and efficacy data from an ongoing phase 1/2 trial of the ADC in patients with advanced/metastatic solid tumors.
"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.
The bill has a mass of legislative supporters – at least 41 senators and 127 representatives, along with more than 370 organizations representing patients, physicians, hospitals and Medicare Advantage plans.
Data from SEER showed a median OS of 23.0 months between the years 2000 to 2004 in patients with mHSPC, which increased to 30.0 months in 2015 to 2019.
Subcutaneous nivolumab is also under review in the United States based on findings from the phase 3 CheckMate-67T trial.
"The medical necessity of the service needs to be expressed within the documentation submitted," write Jonathan Rubenstein, MD, and Mark Painter.
N-803 was approved by the FDA in April 2024 for the treatment of patients with BCG-unresponsive NMIBC carcinoma in situ with or without papillary tumors.
A novel co-formulation of bremelanotide and a PDE5 inhibitor allows the treatment to be administered to patients via a single injection.
Patients in the Cxbladder arm had a 59% relative reduction in the number of cystoscopies performed vs those in the control arm.
"As the markets continue to push record highs, staying disciplined in your investment strategy, removing emotion from your decision-making, and sticking to an appropriate investment allocation will be vital to navigating market swings," writes Jeff Witz, CFP.
"This study reinforces our role as physicians to guide patients away from costly supplements with little or no benefit," said Wai Lee, MD.
"I think digital therapeutics and virtual care are going to expand access," says David Sheyn, MD.
The new Category I code will become effective on January 1, 2026.
Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.
"The positive trends emerging from the ongoing phase 1 trial of BMC128, particularly in combination with nivolumab, underscore the transformative potential of microbiome-based therapeutics in oncology,” says Gal Markel, MD, PhD, MBA.
The first commercial doses of the diagnostic have now been administered in both Austria and France.
"What we believe is happening is women are seeking the help of female urologists, and therefore, because of the nature of the condition, the female urologists are absorbing the burden of the care of these patients, particularly the non-billable burden," says Debra L. Fromer, MD.
Disitamab vedotin is a novel humanized anti-HER2 antibody-drug conjugate that previously demonstrated encouraging anti-tumor activity in combination with toripalimab in patients with metastatic urothelial carcinoma.
"There's obviously a huge interest in focal therapy for prostate cancer, largely because we want to try to prevent the overtreatment of prostate cancer and also develop better approaches to deliver high-quality treatment options for patients," says Timothy D. McClure, MD.
"[The care plan] incorporates patient-specific data to reinforce dietary management, fluid intake, and medication adherence based on the patient's 24-hour urine collection results," says Jenny Guo, MD.
The 12-month duration of response was 82.3% among patients with LG-IR-NMIBC who achieved a complete response at 3 months following the first UGN-102 instillation.
“Our trial’s preliminary major finding is that PSCA-directed CAR T cells may be effective against mCRPC," says Saul J. Priceman, PhD.
"Overall, I think this study will allow clinicians to better advise patients in the slightly complex landscape of OAB therapies," says Leo Dreyfuss, MD.
The median progression-free survival with the combination was 19.83 months.
The negative margin rate was 72.8% with UnfoldAI vs 1.6% with SOC, translating to a 45-fold increase in accurately identifying cancer extent with the AI tool.
